Make A Donation!

Help us cover the cost of running this website and help with the fight against hepatitis C! We appreciate your support!

Magazine - The Hep Factor

The Hep Factor - Thanks to the Hepatitis C Council of Queensland

Web Version | Print Version

Magazine - Hep C Review

The Hep C Review - Thanks to the Hepatitis C Council of NSW

Part 1 | Part 2

Hep C Community News

Hep C Community News - Thanks to the Hepatitis C Council of South Australia

Magazine - Good Liver

Good Liver - Thanks to the Hepatitis C Council of Victoria
Early Treatment Is Key To Combating Hepatitis C Virus PDF Print E-mail
Saturday, 09 August 2008 14:20

ScienceDaily (Aug. 8, 2008) — Canadian researchers have shown that patients who receive early treatment for Hepatitis C virus (HCV) within the first months following an infection, develop a rapid poly-functional immune response against HCV similar to when infection is erradicted spontaneously, according to a new study.

Therefore, early treatment can restore immune response against HCV and help eliminate the virus rapidly. This new discovery of the mechanisms of viral eradication could contribute to the development of new treatments.

 

About a quarter of infected individuals eradicate the infection spontaneously, without treatment. Led by Dr. Naglaa Shoukry and Dr. Julie Bruneau, affiliated to both the Research Centre of the Université de Montréal Hospital Centre and the Université de Montréal, as well as with researchers from the Institut national de la santé et de la recherché scientifique (Montréal branch), the study found that early treatment restores a rapid poly-functional immune response, characterized by the simultaneous production of multiple antiviral mediators.

HCV is transmitted through infected blood. Although a quarter of infected patients can eradicate the infection spontaneously, the majority develop persistent infection, a major cause of cirrhosis and cancer of the liver. The only approved treatment for HCV is an anti-viral drug known as pegylated interferon alpha. This drug is successful in only half of cases when administered during chronic infection. Success rates among those treated early after infection are significantly higher or around 90%.

In North America alone, most new HCV infections occur among intravenous drug users (IDUs), a vulnerable population that is often undiagnosed and untreated. In the study, researchers followed a group of IDUs at high risk of HCV infection before and immediately after exposure to HCV. Their findings clearly show the importance of early diagnosis and treatment of HCV – particularly in marginalized populations such as IDUs and aboriginal populations.

The study was funded by Canadian Institutes of Health Research and the Fonds de la recherché en santé du Québec.

 

Comments (0)add comment

Write comment
smaller | bigger
password
 

busy
 

Site, Article & Information Disclaimer

All information and articles provided on our website and forums are to be used as a guideline only. For your own safety, please always consult with a doctor or specialist before making any decisions regarding your health care. By visiting this website you instantly adhere to this policy.